SGMT · Sagimet Biosciences Inc.

The leadership transition in the Chief Medical Officer role reflects a planned succession at Sagimet Biosciences, with Dr. Martins retiring after his tenure and transitioning to an external scientific advisory capacity. Dr. Grauer brings extensive clinical development and executive leadership experience across multiple biopharmaceutical companies, including recent CMO roles at Omeros, Federation Bio, and Corcept, as well as over a decade at Amgen in global development. His academic appointment at the University of Heidelberg underscores continued engagement in medical education and endocrinology—areas aligned with Sagimet’s metabolic disease focus. While the filing does not disclose compensation terms or strategic rationale for the appointment, the continuity of leadership on the same effective date minimizes operational disruption. For investors, this change signals stability in clinical strategy execution but introduces no disclosed near-term programmatic or financial implications.